• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.

作者信息

Higano Celestia S

机构信息

From the University of Washington, Seattle.

出版信息

N Engl J Med. 2020 Jun 4;382(23):2257-2259. doi: 10.1056/NEJMe2016433. Epub 2020 May 29.

DOI:10.1056/NEJMe2016433
PMID:32469186
Abstract
摘要

相似文献

1
Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.心血管疾病与前列腺癌的雄激素轴靶向药物
N Engl J Med. 2020 Jun 4;382(23):2257-2259. doi: 10.1056/NEJMe2016433. Epub 2020 May 29.
2
Androgen deprivation therapy for prostate cancer and cardiovascular death.前列腺癌的雄激素剥夺治疗与心血管死亡
JAMA. 2012 Mar 28;307(12):1252; author reply 1252-3. doi: 10.1001/jama.2012.352.
3
Cardiovascular risk during androgen deprivation therapy for prostate cancer.前列腺癌雄激素剥夺治疗期间的心血管风险。
BMJ. 2011 May 24;342:d3105. doi: 10.1136/bmj.d3105.
4
Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.雄激素剥夺疗法治疗前列腺癌的心血管效应：降低前列腺癌患者心血管疾病的ABCDE步骤
Circulation. 2016 Feb 2;133(5):537-41. doi: 10.1161/CIRCULATIONAHA.115.012519.
5
Androgen deprivation therapy for prostate cancer: friend or foe to the cardiovascular system?前列腺癌的雄激素剥夺治疗：对心血管系统是福是祸？
World J Urol. 2016 Jun;34(6):879-81. doi: 10.1007/s00345-015-1700-7. Epub 2015 Sep 30.
6
Long term androgen deprivation therapy in prostate cancer.前列腺癌的长期雄激素剥夺治疗
BMJ. 2008 Sep 22;337:a1361. doi: 10.1136/bmj.a1361.
7
[Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].[雄激素剥夺疗法治疗激素依赖性前列腺癌的心血管风险：促性腺激素释放激素拮抗剂与促性腺激素释放激素激动剂之间的差异]
Herz. 2016 Dec;41(8):697-705. doi: 10.1007/s00059-016-4422-8. Epub 2016 Apr 15.
8
Cardiovascular risks of androgen deprivation therapy.雄激素剥夺疗法的心血管风险。
Arq Bras Cardiol. 2010 Sep;95(3):412-5. doi: 10.1590/s0066-782x2010001300019.
9
Androgen deprivation therapy for prostate cancer.前列腺癌的雄激素剥夺治疗
Lancet Oncol. 2017 Oct;18(10):e567. doi: 10.1016/S1470-2045(17)30670-8. Epub 2017 Sep 1.
10
Androgen suppression therapy and prostate cancer: balancing the harms and the benefits.
Cancer. 2008 Dec 15;113(12):3275-8. doi: 10.1002/cncr.23971.

引用本文的文献

1
Management of Advanced Prostate Cancer With Relugolix: Illustrative Case Scenarios From an Advanced Practice Provider Perspective.使用瑞卢戈利治疗晚期前列腺癌：从高级执业提供者角度看的实例情况
J Adv Pract Oncol. 2024 Jan;15(1):43-55. doi: 10.6004/jadpro.2024.15.1.5. Epub 2024 Jan 1.
2
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide.内体再循环抑制剂下调雄激素受体并与恩扎卢胺协同作用。
Invest New Drugs. 2024 Feb;42(1):14-23. doi: 10.1007/s10637-023-01407-x. Epub 2023 Nov 14.
3
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
在晚期前列腺癌中，从 HERO 研究看伴随心血管治疗对瑞戈非尼与亮丙瑞林疗效和安全性的影响：亚组分析。
Adv Ther. 2023 Nov;40(11):4919-4927. doi: 10.1007/s12325-023-02634-7. Epub 2023 Sep 15.
4
Allostatic load and cardiovascular outcomes in males with prostate cancer.男性前列腺癌患者的应激负荷与心血管结局。
JNCI Cancer Spectr. 2023 Mar 1;7(2). doi: 10.1093/jncics/pkad005.
5
Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques.前列腺癌不断发展的成像方法及磁共振成像引导消融技术的出现。
Front Oncol. 2022 Nov 17;12:1043688. doi: 10.3389/fonc.2022.1043688. eCollection 2022.
6
Cardiac risk factors and events in patients with prostate cancer commencing androgen deprivation therapy: analysis from a tertiary care centre in the Middle East.开始雄激素剥夺治疗的前列腺癌患者的心脏危险因素及事件：来自中东一家三级护理中心的分析
Ecancermedicalscience. 2022 Sep 14;16:1445. doi: 10.3332/ecancer.2022.1445. eCollection 2022.
7
Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence.评估和缓解前列腺癌患者的心血管风险：证据综述。
Int J Clin Pract. 2022 May 17;2022:2976811. doi: 10.1155/2022/2976811. eCollection 2022.
8
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.前列腺癌患者中地加瑞克与亮丙瑞林的心血管安全性：PRONOUNCE 随机试验的主要结果。
Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30.
9
Does Exist a Differential Impact of Degarelix LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies.是否存在 Degarelix LHRH 激动剂对心血管安全性的差异影响？来自随机和真实世界研究的证据。
Front Endocrinol (Lausanne). 2021 Jun 14;12:695170. doi: 10.3389/fendo.2021.695170. eCollection 2021.